UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

Haematologica (Roma), 2021-04, Vol.106 (4), p.1034-1046

2021

Volltextzugriff (PDF)

Leveraging Humanized Animal Models to Understand Human Drug Disposition: Opportunities, Challenges, and Future Directions

Clinical pharmacology and therapeutics, 2018-02, Vol.103 (2), p.188-192

2018

Volltextzugriff (PDF)

Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300

Journal of medicinal chemistry, 2016-12, Vol.59 (23), p.10549-10563

2016

Volltextzugriff (PDF)

Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer

Cancer research (Chicago, Ill.), 2017-10, Vol.77 (20), p.5564-5575

2017

Volltextzugriff (PDF)

A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation―Driven Colorectal Tumor Growth

Cancer research (Chicago, Ill.), 2013-05, Vol.73 (10), p.3132-3144

2013

Volltextzugriff (PDF)

Identification of a Discrete Diglucuronide of GDC-0810 in Human Plasma after Oral Administration

Drug metabolism and disposition, 2023-10, Vol.51 (10), p.1284-1294

2023

Volltextzugriff (PDF)

GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)

Journal of medicinal chemistry, 2017-11, Vol.60 (22), p.9162-9183

2017

Volltextzugriff (PDF)

Bioactivation of α , β -Unsaturated Carboxylic Acids Through Acyl Glucuronidation

Drug metabolism and disposition, 2020-09, Vol.48 (9), p.819-829

2020

Volltextzugriff (PDF)

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response

Clinical cancer research, 2012-07, Vol.18 (14), p.3846-3855

2012

Volltextzugriff (PDF)

Role of P‑Glycoprotein on the Brain Penetration and Brain Pharmacodynamic Activity of the MEK Inhibitor Cobimetinib

Molecular pharmaceutics, 2014-11, Vol.11 (11), p.4199-4207

2014

Volltextzugriff (PDF)

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

Clinical cancer research, 2012-06, Vol.18 (11), p.3090-3099

2012

Volltextzugriff (PDF)

Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors

Journal of medicinal chemistry, 2019-07, Vol.62 (13), p.6223-6240

2019

Volltextzugriff (PDF)

A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors

Journal of medicinal chemistry, 2017-12, Vol.60 (24), p.10151-10171

2017

Volltextzugriff (PDF)

Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug–Drug Interactions

Molecular pharmaceutics, 2017-05, Vol.14 (5), p.1754-1759

2017

Volltextzugriff (PDF)

Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor

Drug metabolism and disposition, 2015-06, Vol.43 (6), p.864-869

2015

Volltextzugriff (PDF)

Overview of SLC22A and SLCO families of drug uptake transporters in the context of cancer treatments

Current drug metabolism, 2011-10, Vol.12 (8), p.793-807

2011

Volltextzugriff (PDF)

Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects

Journal of clinical pharmacology, 2018-11, Vol.58 (11), p.1427-1435

2018

Volltextzugriff (PDF)

Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs

Toxicologic pathology, 2020-04, Vol.48 (3), p.465-480

2020

Volltextzugriff (PDF)

The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199

Drug metabolism and disposition, 2014-02, Vol.42 (2), p.207-212

2014

Volltextzugriff (PDF)

Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1

ACS medicinal chemistry letters, 2024-09, Vol.15 (9), p.1606-1614

2024

Volltextzugriff (PDF)

Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans

Drug metabolism and disposition, 2016-01, Vol.44 (1), p.28-39

2016

Volltextzugriff (PDF)

Assessment of OATP transporter‐mediated drug–drug interaction using physiologically‐based pharmacokinetic (PBPK) modeling – a case example

Biopharmaceutics & drug disposition, 2018-11, Vol.39 (9), p.420-430

2018

Volltextzugriff (PDF)

Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300

Bioorganic & medicinal chemistry letters, 2018-01, Vol.28 (1), p.15-23

2018

Volltextzugriff (PDF)

Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)

ACS medicinal chemistry letters, 2022-01, Vol.13 (1), p.84-91

2022

Volltextzugriff (PDF)

Elucidating the Mechanisms of Formation for Two Unusual Cytochrome P450-Mediated Fused Ring Metabolites of GDC-0623, a MAPK/ERK Kinase Inhibitor

Drug metabolism and disposition, 2015-12, Vol.43 (12), p.1929-1933

2015

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(74)
magazinearticle
(1)

Sprache

Englisch
(75)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(58)
Science & Technology
(58)
Pharmacology & Pharmacy
(48)
Animals
(35)
Humans
(33)
Mice
(25)
Female
(23)
Male
(20)
Biological And Medical Sciences
(15)
Chemistry, Medicinal
(14)
Medical Sciences
(14)
Antineoplastic Agents - Pharmacokinetics
(13)
Cell Line, Tumor
(12)
Xenograft Model Antitumor Assays
(12)
Mice, Nude
(11)
Rats
(11)
Dogs
(10)
Pharmacology. Drug Treatments
(10)
Administration, Oral
(9)
Oncology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

Leveraging Humanized Animal Models to Understand Human Drug Disposition: Opportunities, Challenges, and Future Directions

Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300

Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer

A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation―Driven Colorectal Tumor Growth

Identification of a Discrete Diglucuronide of GDC-0810 in Human Plasma after Oral Administration

GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)

Bioactivation of α , β -Unsaturated Carboxylic Acids Through Acyl Glucuronidation

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response

Role of P‑Glycoprotein on the Brain Penetration and Brain Pharmacodynamic Activity of the MEK Inhibitor Cobimetinib

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors

A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors

Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug–Drug Interactions

Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor

Overview of SLC22A and SLCO families of drug uptake transporters in the context of cancer treatments

Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects

Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs

The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199

Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1

Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans

Assessment of OATP transporter‐mediated drug–drug interaction using physiologically‐based pharmacokinetic (PBPK) modeling – a case example

Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300

Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)

Elucidating the Mechanisms of Formation for Two Unusual Cytochrome P450-Mediated Fused Ring Metabolites of GDC-0623, a MAPK/ERK Kinase Inhibitor

Suchergebnisse filtern